Marshall Wace, LLP Protara Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 77,351 shares of TARA stock, worth $416,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77,351
Previous 77,351
-0.0%
Holding current value
$416,921
Previous $160,000
11.88%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TARA
# of Institutions
39Shares Held
10.7MCall Options Held
9KPut Options Held
1.8K-
Ra Capital Management, L.P. Boston, MA1.9MShares$10.2 Million0.05% of portfolio
-
Opaleye Management Inc. Boston, MA1.68MShares$9.06 Million0.56% of portfolio
-
Stem Point Capital LP New York, NY943KShares$5.08 Million0.52% of portfolio
-
Woodline Partners LP San Francisco, CA852KShares$4.59 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA812KShares$4.37 Million0.08% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $60.7M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...